Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

• Main Authors: Tingting Zhao (Author), Xuening Li (Author), Yanwei Chen (Author), Jie Du (Author), Xiaodong Chen (Author), Dalong Wang (Author), Liyan Wang (Author), Shan Zhao (Author), Changyuan Wang (Author), Qiang Meng (Author), Huijun Sun (Author), Kexin Liu (Author), Jingjing Wu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or prophylaxis in clinical practice. The present study ai...